Vaccine candidate shows promise in human trials: CNBG

The experimental shot, developed by a Beijing-based unit of CNBG, has induced high-level antibodies in all the inoculated participants in a Phase 1/2 clinical trial involving 1,120 healthy people, according to preliminary data of the trial, CNBG said in a posting on the social media platform WeChat

from News-Economic Times https://ift.tt/2CIjOF4